|
|
Pentraxin PTX3 - a new marker of immunopathological inflammation.
Kondělková, Kateřina ; Jílek, Petr (advisor) ; Andrýs, Ctirad (referee)
Pentraxin 3 (PTX3) is a newly identified acute phase reactant which shares some structural and some functional properties with CRP, classical short pentraxin. On the other hand, PTX3 displays unique biological properties of its own, including a possible role in the pathogenesis of cardiovascular diseases and in processes accompanying the natural evolution of surgical wounds. Unlike CRP, which is manufactured predominatly in the liver, PTX3 is produced especially at sites of tissue damage. PTX3 synthesis is induced by proinflammatory cytokines TNF-α or IL-1β and by microbial wall constituents such as the lipololysaccharide (LPS). Plasma protein PTX3 concentrations are elevated in a wide range of diseased states, such as in coronary artery disease, in pulmonary infection and acute lung injury, 3 in patients with chronic kidney disease, in pacients with depression, during normal pregnancy and preeclampsia, in pacients with psoriasis and during cardiac surgery with or without cardiopulmonary bypass. PTX3 was detected using detection set (Alexis Biochemicals, Switzerland) cat.no. ALX- 850-299-KI01 for sandwich ELISA application that provided capture monoclonal antibody to PTX3, detection polyclonal antibody to PTX3 and recombinant PTX3 (standard). Goeckerman's therapy of psoriasis is highly efficient in...
|
|
|
The effect of Goeckerman therapy on selected immune markers in patients with psoriasis
Kondělková, Kateřina ; Andrýs, Ctirad (advisor) ; Posová, Helena (referee)
1 Summary The effect of Goeckerman therapy on selected immune markers in patients with psoriasis Psoriasis is a systemic inflammatory disorder with skin manifestation. Classical approach to treat psoriasis is Goeckerman therapy (GT) which is based on daily application of pharmaceutical coal tar on affected skin with subsequent exposition to UV light. The aim of this study was to observe selected immunological markers and cell subpopulations in patients with psoriasis and to elucidate the effect of GT on these parameters. We evaluated T regulatory cells (Treg), membrane CD163 expression on monocytes, serum levels of CD163 (sCD163), membrane TLR2 and TLR4 expression on monocytes and serum levels of TLR2 (sTLR2). The immunofluorescent analysis was performed on erythrocyte lysed peripheral blood using a flow cytometer FC500 Cytomics (Beckman Coulter) and FACSCalibur (Becton Dickinson). The level of soluble markers was detected by sandwich enzyme-liked immunosorbent assay (ELISA). There was no significant difference in the relative number of Treg cells in the peripheral blood of healthy blood donors and patients with psoriasis before initiation of GT. The relative number of Treg is significantly increased in psoriatic patients after GT compared to the pre-treatment level. In comparison with levels in controls...
|
|
|
The effect of Goeckerman therapy on selected immune markers in patients with psoriasis
Kondělková, Kateřina ; Andrýs, Ctirad (advisor) ; Weigl, Evžen (referee) ; Posová, Helena (referee)
1 Summary The effect of Goeckerman therapy on selected immune markers in patients with psoriasis Psoriasis is a systemic inflammatory disorder with skin manifestation. Classical approach to treat psoriasis is Goeckerman therapy (GT) which is based on daily application of pharmaceutical coal tar on affected skin with subsequent exposition to UV light. The aim of this study was to observe selected immunological markers and cell subpopulations in patients with psoriasis and to elucidate the effect of GT on these parameters. We evaluated T regulatory cells (Treg), membrane CD163 expression on monocytes, serum levels of CD163 (sCD163), membrane TLR2 and TLR4 expression on monocytes and serum levels of TLR2 (sTLR2). The immunofluorescent analysis was performed on erythrocyte lysed peripheral blood using a flow cytometer FC500 Cytomics (Beckman Coulter) and FACSCalibur (Becton Dickinson). The level of soluble markers was detected by sandwich enzyme-liked immunosorbent assay (ELISA). There was no significant difference in the relative number of Treg cells in the peripheral blood of healthy blood donors and patients with psoriasis before initiation of GT. The relative number of Treg is significantly increased in psoriatic patients after GT compared to the pre-treatment level. In comparison with levels in controls...
|
|
|
The effect of Goeckerman therapy on selected immune markers in patients with psoriasis
Kondělková, Kateřina ; Andrýs, Ctirad (advisor) ; Weigl, Evžen (referee) ; Posová, Helena (referee)
1 Summary The effect of Goeckerman therapy on selected immune markers in patients with psoriasis Psoriasis is a systemic inflammatory disorder with skin manifestation. Classical approach to treat psoriasis is Goeckerman therapy (GT) which is based on daily application of pharmaceutical coal tar on affected skin with subsequent exposition to UV light. The aim of this study was to observe selected immunological markers and cell subpopulations in patients with psoriasis and to elucidate the effect of GT on these parameters. We evaluated T regulatory cells (Treg), membrane CD163 expression on monocytes, serum levels of CD163 (sCD163), membrane TLR2 and TLR4 expression on monocytes and serum levels of TLR2 (sTLR2). The immunofluorescent analysis was performed on erythrocyte lysed peripheral blood using a flow cytometer FC500 Cytomics (Beckman Coulter) and FACSCalibur (Becton Dickinson). The level of soluble markers was detected by sandwich enzyme-liked immunosorbent assay (ELISA). There was no significant difference in the relative number of Treg cells in the peripheral blood of healthy blood donors and patients with psoriasis before initiation of GT. The relative number of Treg is significantly increased in psoriatic patients after GT compared to the pre-treatment level. In comparison with levels in controls...
|
|
|
Pentraxin PTX3 - a new marker of immunopathological inflammation.
Kondělková, Kateřina ; Jílek, Petr (advisor) ; Andrýs, Ctirad (referee)
Pentraxin 3 (PTX3) is a newly identified acute phase reactant which shares some structural and some functional properties with CRP, classical short pentraxin. On the other hand, PTX3 displays unique biological properties of its own, including a possible role in the pathogenesis of cardiovascular diseases and in processes accompanying the natural evolution of surgical wounds. Unlike CRP, which is manufactured predominatly in the liver, PTX3 is produced especially at sites of tissue damage. PTX3 synthesis is induced by proinflammatory cytokines TNF-α or IL-1β and by microbial wall constituents such as the lipololysaccharide (LPS). Plasma protein PTX3 concentrations are elevated in a wide range of diseased states, such as in coronary artery disease, in pulmonary infection and acute lung injury, 3 in patients with chronic kidney disease, in pacients with depression, during normal pregnancy and preeclampsia, in pacients with psoriasis and during cardiac surgery with or without cardiopulmonary bypass. PTX3 was detected using detection set (Alexis Biochemicals, Switzerland) cat.no. ALX- 850-299-KI01 for sandwich ELISA application that provided capture monoclonal antibody to PTX3, detection polyclonal antibody to PTX3 and recombinant PTX3 (standard). Goeckerman's therapy of psoriasis is highly efficient in...
|
|
| |
|
|
The effect of Goeckerman therapy on selected immune markers in patients with psoriasis
Kondělková, Kateřina ; Andrýs, Ctirad (advisor) ; Posová, Helena (referee)
1 Summary The effect of Goeckerman therapy on selected immune markers in patients with psoriasis Psoriasis is a systemic inflammatory disorder with skin manifestation. Classical approach to treat psoriasis is Goeckerman therapy (GT) which is based on daily application of pharmaceutical coal tar on affected skin with subsequent exposition to UV light. The aim of this study was to observe selected immunological markers and cell subpopulations in patients with psoriasis and to elucidate the effect of GT on these parameters. We evaluated T regulatory cells (Treg), membrane CD163 expression on monocytes, serum levels of CD163 (sCD163), membrane TLR2 and TLR4 expression on monocytes and serum levels of TLR2 (sTLR2). The immunofluorescent analysis was performed on erythrocyte lysed peripheral blood using a flow cytometer FC500 Cytomics (Beckman Coulter) and FACSCalibur (Becton Dickinson). The level of soluble markers was detected by sandwich enzyme-liked immunosorbent assay (ELISA). There was no significant difference in the relative number of Treg cells in the peripheral blood of healthy blood donors and patients with psoriasis before initiation of GT. The relative number of Treg is significantly increased in psoriatic patients after GT compared to the pre-treatment level. In comparison with levels in controls...
|
guest ::
